Macuject

Cover Block

Name	Macuject
Tagline	Cloud-based SaaS using AI for macular fluid analysis and clinical decisions in wet AMD.
Headquarters	Australia
Founded	2017 [PitchBook, 2025]
Stage	Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Oceania
Growth Profile	Venture Scale
Founding Team	Dr Devinder Chauhan (clinician/ophthalmologist) [Bionics Institute]
Funding Label	Seed
Total Disclosed	$0.62M (estimated) [HealthTechAlpha]

Links

• Website: https://www.macuject.com
• LinkedIn: https://au.linkedin.com/company/macuject

The Short Version

Macuject is a clinician-driven SaaS platform using proprietary AI to standardize and accelerate treatment decisions for wet age-related macular degeneration (AMD) [Macuject.com]. Founded in 2017 by ophthalmologist Dr Devinder Chauhan, the company has progressed from beta testing with Australian specialists to early commercial use in private clinics, with stated plans for a U.S. rollout [mivision 2021, Medium]. Its differentiation lies in integrating automated fluid analysis with patient history dashboards and customizable clinical decision trees.

The executive team brings commercialization and technical experience, with the CTO having led SOC2 and HIPAA compliance efforts [Bradley Beddoes LinkedIn, Crunchbase]. To date, the company has raised approximately $620,000 in total disclosed funding, primarily through participation in the ANDHealth+ accelerator program [HealthTechAlpha, Macuject.com/blog-pages/andhealth-plus]. Over the next 12-18 months, key milestones include the completion of its decision tree for diabetic macular edema, progress toward U.S. Food and Drug Administration clearance, and the translation of early Australian clinic usage into named customer deployments [mivision 2022].

Data Accuracy: YELLOW -- Core product claims are company-sourced and consistent; funding and team details have partial third-party corroboration but lack comprehensive verification.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Oceania
Growth Profile	Venture Scale
Funding	Seed (total disclosed ~$620,000)

The Company in Brief

Macuject is a clinician-founded digital health company established in 2017 and headquartered in Australia [PitchBook, 2025][Bounce Watch]. The company was created by Dr Devinder Chauhan, an ophthalmologist, to address preventable blindness, beginning with wet age-related macular degeneration (AMD) [Bionics Institute].

Key operational milestones have centered on product development and early validation. The platform entered a beta testing phase with a select group of ophthalmologists for several months as of May 2021 [mivision 2021]. By 2022, the company was participating in the ANDHealth+ accelerator program and publicly stated it was seeking capital to complete a decision-making tree for diabetic macular oedema and to pursue regulatory approval for its web app in the United States [mivision 2022][Macuject.com/blog-pages/andhealth-plus]. A compliance milestone for the platform, achieving SOC2 and HIPAA standards, was led by CTO Bradley Beddoes [Bradley Beddoes LinkedIn].

The company's commercial footprint includes use in private clinics in Australia with plans to roll out in the United States [Medium Verge Healthtech]. The executive team includes a Chief Operating Officer and a Chief Commercialisation Officer [Crunchbase].

Data Accuracy: YELLOW -- Core founding date and location corroborated by multiple databases; specific milestones are cited from dated trade press and company blog, but some executive team details lack independent verification.

What They Have Built

The core offering is a cloud-based SaaS platform designed to augment the clinical workflow for ophthalmologists treating wet age-related macular degeneration. The product's differentiation lies in its clinician-driven design, which integrates quantitative fluid measurements with patient history dashboards and customizable decision trees [Macuject.com].

The platform's primary function is the quantitative analysis of macular fluid from Optical Coherence Tomography (OCT) scans using proprietary AI. The company has stated the platform is in use within private clinics in Australia and is preparing for a rollout in the United States [Medium]. As of May 2021, the product was in beta testing with a select group of ophthalmologists [mivision 2021]. A key public milestone was achieving SOC2 and HIPAA compliance [Bradley Beddoes LinkedIn].

Publicly stated development goals include completing a decision-making tree for diabetic macular oedema and pursuing FDA approval for the web application [mivision 2022].

Data Accuracy: YELLOW -- Core product claims are confirmed by the company website and investor blog. Deployment and compliance claims are sourced from a single publication each.

Market Research and Opportunity

The market for AI-assisted ophthalmic diagnostics is defined by a persistent clinical gap between available treatments and patient access. The broader AI in medical imaging market was valued at $1,200M in 2022 and is projected to reach $4,500M by 2028 [PitchBook, 2025].

Demand is driven by demographic aging and the growing burden of chronic eye disease. Age-related macular degeneration is a leading cause of blindness in developed nations, with wet AMD representing the more severe form. While anti-VEGF injections are effective, the regimen requires frequent monitoring and precise, individualized dosing decisions, creating an operational strain on retina specialists.

Metric	Value
AI Medical Imaging Market 2022	$1,200M
AI Medical Imaging Market 2028 (projected)	$4,500M

Data Accuracy: YELLOW -- Market sizing is based on an analogous, broader sector report. Specific TAM for the product's niche is not confirmed.

Who Else Is Fighting for This

Macuject's competitive position is defined by a clinician-first workflow that integrates analysis and decision support.

Company	Positioning	Stage / Funding	Notable Differentiator
Macuject	Cloud-based SaaS for macular fluid analysis and clinical decision trees in wet AMD.	Seed (~$0.62M) [HealthTechAlpha]	Clinician-driven workflow integrating quantitative analysis with customizable decision support.
RetinAI	AI-powered platform for retina image analysis and data management.	Series A ($6M, 2021) [Crunchbase]	Broader focus on data management and analytics across multiple retinal diseases.
Notal Vision	Remote patient monitoring and home-based diagnostic devices for AMD.	Late-stage private ($50M+ raised) [Crunchbase]	Proprietary hardware (ForeseeHome) for at-home monitoring, with established FDA clearances.
RetInSight	AI-based software for automated analysis of retinal OCT scans.	Seed (€1.5M, 2020) [Crunchbase]	Focus on fully automated, CE-marked quantification of retinal fluid and layers.

Macuject's primary edge appears to be its founder-clinician orientation and early Australian clinic integrations. The founder, Dr. Devinder Chauhan, is a practicing ophthalmologist [Bionics Institute]. The company reports its platform is currently used in private clinics in Australia [Medium Verge Healthtech].

Data Accuracy: YELLOW -- Competitor profiles are sourced from Crunchbase; Macuject's differentiation is based on its public materials. The competitive dynamics are inferred from these public positions.

Opportunity

If Macuject can establish its AI-driven workflow as a standard of care in the management of wet AMD, it would capture a portion of a multi-billion dollar global treatment market.

Scenario	What happens	Catalyst	Why it's plausible
Regulatory-Certified Expansion	Macuject achieves FDA clearance for its web app, enabling a formal commercial rollout in the United States.	Successful completion of the FDA approval process [mivision 2022].	The team's CTO has led SOC2 and HIPAA compliance efforts [Bradley Beddoes LinkedIn].
Pharma Partnership & Embedded Use	The platform is adopted by pharmaceutical companies as a companion tool for clinical trials and therapy monitoring.	A partnership with a manufacturer of OCT devices or a drug developer.	The company lists pharma companies and OCT manufacturers as target customers [Macuject.com].

Data Accuracy: YELLOW -- Opportunity framing is based on company-stated goals and early use evidence; specific market size and comparable valuation data are not independently confirmed.

Sources

1. [PitchBook, 2025] Macuject 2025 Company Profile | https://pitchbook.com/profiles/company/520529-14
2. [Bionics Institute] From clinician to entrepreneur with Dr Devinder Chauhan - Bionics Institute | https://www.bionicsinstitute.org/podcasts-videos-media/from-clinician-to-entrepreneur-with-dr-devinder-chauhan/
3. [Macuject.com] Macuject | https://www.macuject.com/
4. [mivision, 2021] Paying it Forward: A Free AI Solution to Improve Outcomes for nAMD - mivision | https://mivision.com.au/2022/05/paying-it-forward-a-free-ai-solution-to-improve-outcomes-for-namd/
5. [Medium, Unknown] Why We Invested in Macuject. by Scarlett Chen | https://medium.com/verge-healthtech/why-we-invested-in-macuject-b9a937c150ed
6. [Macuject.com/blog-pages/andhealth-plus] Macuject Blog - ANDHealth+ | https://www.macuject.com/blog-pages/andhealth-plus
7. [Bradley Beddoes LinkedIn] Bradley Beddoes - Greater Brisbane Area | Professional Profile | LinkedIn | https://www.linkedin.com/in/bradleybeddoes/
8. [Crunchbase] Macuject Company Profile | https://www.crunchbase.com/organization/macuject
9. [Bounce Watch] Macuject - AI, Health Care Company Profile, Funding Rounds and Investors - Bounce Watch | https://bouncewatch.com/explore/startup/macuject
10. [HealthTechAlpha] Macuject | https://www.healthtechalpha.com/venture/macuject
11. [mivision, 2022] Paying it Forward: A Free AI Solution to Improve Outcomes for nAMD - mivision | https://mivision.com.au/2022/05/paying-it-forward-a-free-ai-solution-to-improve-outcomes-for-namd/
12. [CBInsights] Macuject CBInsights | https://www.cbinsights.com/company/macuject